MSD Korea made its highest-ever sales last year, recording annual sales of KRW 820.4 billion last year. The strong sales of Keytruda and Gardasil 9 greatly contributed to the company’s external growth. However, the increase in sales costs and SG&A expenses cut the company’s operating profit by half.

According to the Financial Supervisory Service on the 14th, MSD Korea recorded sales of KRW 820.4 billion last year. This is a 51% increase from last year's KRW 541.9 billion.

MSD’s sales, which had been KRW 271.6 billion in 2019, then KRW 484.7 billion in 2020, had exceeded KRW 500 billion in 2021. Last year, sales surged by approximately KRW 280 billion to reach KRW 800 billion. Over the pas